Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several noteworthy findings. According to the announcement, unlimited food and water have been provided to the animals for the entire duration of the study. During the initial acclimation phase, which spanned 34 days before the beginning of dosing, the animals gained 10.9% body weight on average. During the subsequent 28 days of DehydraTECH-processed drug therapy dosing, all test articles showed either a stark decrease in the rate of body weight gain or, in select cases, the beginning of body weight reduction. Lexaria noted that DehydraTECH-CBD formulation 3 (“CBD3”) and DehydraTECH-liraglutide produced the largest weight loss results thus far -1.50% and -1.58% body weight reduction, respectively. This is the first time the company has applied DehydraTECH processing to the GLP-1 drug liraglutide. Lexaria is encouraged to witness its relative outperformance, which suggests that DehydraTECH appears to work with a second GLP-1 drug after semaglutide. In addition, DehydraTECH appears to be working with semaglutide both with and without the sodium salcaprozate (“SNAC”) technology. The announcement noted that only in study arms A, B, C, and E did any individual animals lose 5.0% or more body weight during the first 28 days of treatment. An additional 56 days of dosing remains across all treatment groups. According to the announcement, dosing in the final four study arms that constitute Cohort 2 of the study has begun and is expected to be completed in mid-October. Cohort 2 includes the best performers from Cohort 1 of the study, which comprises the first eight study arms.
To view the full press release, visit https://cnw.fm/RH0k8
About Lexaria Bioscience Corp.
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]
CannabisNewsWire is powered by IBN